Lantheus (LNTH) Proxy filing summary

Executive summary

• A definitive agreement was signed for the acquisition of the company by Curium, a global radiopharmaceutical leader, for $102.50 per share in cash plus up to $12.00 per share in contingent value rights (CVRs), with a total potential transaction value of approximately $8.0 billion.

• The merger will create a combined company with complementary strengths across the nuclear medicine value chain, spanning isotope production, manufacturing, diagnostic imaging, and targeted radionuclide therapy, serving over 70 countries.

• The transaction is expected to close in the first half of 2027, subject to shareholder and regulatory approvals; until then, the company will continue to operate independently with no disruption to ongoing initiatives or supply.

• The board, after a comprehensive review of strategic options, unanimously determined this transaction as the best value-maximizing path for shareholders.

• All ongoing product launches and initiatives, including PYLARIFY TruVu, will proceed on current timelines, and employees' roles and responsibilities remain unchanged until closing.

Voting matters and shareholder proposals

• Shareholders will be asked to approve the merger at a special meeting, with proxy materials to be distributed in advance.

• The transaction requires approval by shareholders and satisfaction of customary closing conditions, including regulatory approvals.

Board of directors and corporate governance

• The board, with financial advisors, evaluated multiple strategic options before unanimously approving the merger.

• The CEO search process has been paused to focus on the merger, with current leadership continuing until closing.